Accelerator Corporation Finances Twelfth Startup with Oncofactor Corporation

Research effort to be led by Institute for Systems Biology-Accelerator Venture Fellow Graduate

SEATTLE--(BUSINESS WIRE)-- Accelerator Corporation, a privately held, venture-capital-backed biotechnology investment and development company, announced today the Series A financing of Oncofactor Corporation. This is the twelfth company backed by Accelerator and its first investment based on internal intellectual property developed at Accelerator. Oncofactor is developing cancer therapeutics that disrupt signaling pathways between tumors and the immune system. The investors participating in the Series A investment in Oncofactor include Accelerator syndicate partners: Alexandria Real Estate Equities; Amgen Ventures; ARCH Venture Partners, Inc.; OVP Venture Partners; PPD, Inc.; and WRF Capital.

Sarah Warren, Ph.D., will lead Oncofactor as Director of Discovery & Validation. Dr. Warren was first introduced to Accelerator as an Institute for Systems Biology (ISB)-Accelerator Venture Fellow in 2008. The fellowship provides hands-on training for ISB employees interested in biotechnology and the process of commercializing new technologies. Fellows interact with scientists and investors at Accelerator to help evaluate ground-breaking emerging life sciences opportunities.

While a fellow at Accelerator, Dr. Warren was a graduate student in the University of Washington’s Department of Immunology. She completed her thesis work with Dr. Alan Aderem at the ISB, where she investigated early signaling events that control the magnitude of immune response. This work culminated in significant enhancements to Listeria monocytogenes-based vaccines that will have implications for vaccines against cancer and infectious disease. Additionally, Dr. Warren joined the Molecular Medicine Program at the University of Washington, a certificate program designed to train students to integrate basic research with clinical experiences in human disease.

Dr. Warren’s scientific training began at Iowa State University, where as a National Merit Scholar she double majored in biochemistry and English. During her time at Iowa State, Dr. Warren participated in summer research programs with the National Science Foundation, the National Institutes of Health, and the Mayo Clinic.

“We are pleased to announce our 12th Accelerator investment and are thrilled to see one of our ISB Accelerator Venture Fellows lead the research effort at a portfolio company,” said Carl Weissman, Chairman and CEO of Accelerator. “Sarah has been deeply involved in the Oncofactor effort since its earliest days at Accelerator. Working in close collaboration with Oncofactor’s Research Advisory Committee that consists of a group of biotechnology research and drug development veterans, I am confident that Sarah and the Oncofactor team can execute on its ambitious research plan,” added Weissman.

“The Oncofactor technology platform represents an opportunity to address cancer from the perspective of the immune system,” stated Chad Waite, Managing Director of OVP Venture Partners. “We look forward to supporting this novel approach by a new entrepreneur.”

About Accelerator Corporation

Accelerator Corporation, founded in 2003, is a privately held biotechnology investment and development company located in Seattle, Washington, USA. The company is building the next generation of life-enhancing biotechnology companies by providing the resources critical to accelerating the development of nascent leading-edge biotechnologies. These key resources, provided by global life science leaders – Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD, Inc., Alexandria Real Estate Equities, Inc., WRF Capital, and the Institute for Systems Biology - include committed capital from top-tier venture capital firms, state-of-the-art facilities, world-class scientific and technical expertise and support, and experienced biotechnology start-up business management and support. For more information, please go to: www.acceleratorcorp.com.



CONTACT:

Accelerator Corporation
Jessica Burback, 206-957-7300
[email protected]

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Research  Science

MEDIA:

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.